Diabetes
Conference Coverage
Once-weekly basal insulin nears market for type 2 diabetes
“I feel that weekly insulins have the potential to become transformational as preferred options for basal insulin replacement in people with type...
Conference Coverage
ADA: Screen all with type 2 diabetes for fatty liver disease
The ADA now advises screening all adults with type 2 diabetes or prediabetes, particularly those with obesity or cardiometabolic risk factors or...
News
SAFE algorithm detects liver disease in general population
Scoring system was developed and validated to detect clinically significant (greater than stage 2) fibrosis in patients with NAFLD in primary care...
Conference Coverage
Children with type 2 diabetes face dire complications as young adults
Arterial stiffness and worsened cardiac function often appear in these children within 2-5 years of diagnosis and seem driven in part by the...
Conference Coverage
OASIS and PIONEER PLUS support high-dose oral semaglutide
OASIS-1 showed that “oral semaglutide 50 mg may represent an effective option for the treatment of obesity, particularly in patients who prefer...
Conference Coverage
‘Striking’ benefit of lipid lowering in primary prevention
“If patients can’t tolerate a statin, then treat them with bempedoic acid. The bottom line is that these patients just need to be treated.”
Conference Coverage
SURMOUNT-2: Tirzepatide rings up major weight loss in type 2 diabetes
Taken together, results from SURMOUNT-1 and SURMOUNT-2 appear to make a good case for a weight-loss indication that will not depend on whether a...
News
Low copays drive better adherence to new diabetes drugs
Regardless of patients’ socioeconmic status, copays were related to adherence.
News
Is education or screening better for type 1 diabetes?
Despite the impressive data from the FR1DA study, not all diabetes experts are convinced that a general screening for type 1 diabetes would be...
News from the FDA/CDC
FDA OKs empagliflozin for children with type 2 diabetes
This approval represents only the second oral treatment option for children and adolescents with type 2 diabetes after metformin.